share_log

BTIG Initiates Coverage On MariMed With Buy Rating, Announces Price Target of $0.85

BTIG Initiates Coverage On MariMed With Buy Rating, Announces Price Target of $0.85

BTIG以买入评级启动对MariMed的报道,宣布目标股价为0.85美元
Benzinga Real-time News ·  2022/10/28 09:18

BTIG analyst Jonathan Decourcey initiates coverage on MariMed (OTC:MRMD) with a Buy rating and announces Price Target of $0.85.

BTIG分析师乔纳森·德库西以买入评级开始对MariMed(场外交易代码:MRMD)进行报道,并宣布目标股价为0.85美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发